Erratum: Corrigendum to “Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction” (Journal of Cardiac Failure (2016) 22(6) (423–432)(S1071916416000671)(10.1016/j.cardfail.2016.02.007))

Yuya Matsue, Makoto Suzuki, Sho Torii, Satoshi Yamaguchi, Seiji Fukamizu, Yuichi Ono, Hiroyuki Fujii, Takeshi Kitai, Toshihiko Nishioka, Kaoru Sugi, Yuko Onishi, Makoto Noda, Nobuyuki Kagiyama, Yasuhiro Satoh, Kazuki Yoshida, Steven R. Goldsmith

Research output: Contribution to journalComment/debatepeer-review

3 Scopus citations

Abstract

The authors regret that on page 429, in the Discussion section of the Aquamarine trial, the ASCEND trial is incorrectly described. The actual title is ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). The reference (21) is correct. Also on page 429, the RELAX-AHF trial is incorrectly cited. The correct trial referred to is PROTECT. Reference 22 should be: Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, et al, PROTECT Investigators and Committees. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010;363:1419-28. The authors apologize for any inconvenience caused.

Original languageEnglish (US)
Pages (from-to)941
Number of pages1
JournalJournal of cardiac failure
Volume22
Issue number11
DOIs
StatePublished - Nov 1 2016

Bibliographical note

Publisher Copyright:
© 2016 Elsevier Inc.

Fingerprint

Dive into the research topics of 'Erratum: Corrigendum to “Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction” (Journal of Cardiac Failure (2016) 22(6) (423–432)(S1071916416000671)(10.1016/j.cardfail.2016.02.007))'. Together they form a unique fingerprint.

Cite this